Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma

生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘

• 批准号: 10589800
• 负责人: OFER LEVY
• 金额: $ 154.65万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-10 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10589800
• 关键词: Acceleration; Adjuvant; Adult; Africa; Age; Asthma; Australasia; Bacteria; Bioinformatics; Biological Assay; Biological Markers; Biological Models; Birth; Blood Donations; Blood Volume; Cells; Childhood; Clinical; Communicable Diseases; Coupled; Data; Development; Disease; Enrollment; Epigenetic Process; Goals; Greek; Growth; Health; Human; Human body; Immune; Immune system; Immunity; Immunologics; Immunomodulators; In Vitro; Individual; Infant; Infection; Innate Immune Response; Intervention; Knowledge; Life; Liquid substance; Measures; Mediating; Medical; Memory; Modeling; Molecular; Molecular Profiling; Mucous Membrane; Newborn Infant; North America; Nose; Organ; PRTN3 gene; Pathway interactions; Pattern; Pediatric cohort; Phenotype; Physiological; Plasma; Positioning Attribute; Predisposition; Prognostic Marker; Protective Agents; Proteins; Proteomics; Publishing; Resistance; Respiratory Disease; Respiratory Tract Infections; Risk; Sampling; Shapes; System; Systems Biology; Testing; Training; Translating; Vaccines; Validation; adaptive immune response; age related; biobank; bioinformatics tool; clinical phenotype; cohort; experience; gut microbiome; high risk; in silico; in utero; in vitro Model; infancy; infection risk; insight; inter-individual variation; metabolomics; microbiome; multiple omics; novel strategies; predictive marker; prevent; programs; prospective; respiratory; response; risk prediction; specific biomarkers; tool; vaccine response

PROJECT SUMMARY To date, efforts to define and apply precision endotyping has been limited to studies of adults. However, immune development in early life (IDEAL) is dynamic and varies between individuals suggesting that endotypes corresponding to distinct pathophysiological mechanisms will be age-dependent. We propose therefore a novel approach in which we will study well-defined longitudinal childhood cohorts and use in silico integrative analyses of existing and prospectively collected data coupled with age-specific human in vitro model systems to identify agents that redirect IDEAL away from disease endotypes towards those associated with health. We have selected three clinical endpoints to correlate with systems biology data to identify IDEAL endotypes: a) vaccine responsiveness, as vaccines are the most important biomedical intervention to reduce childhood disease; b) respiratory infection which represents the greatest burden of childhood infectious disease; and c) asthma, an immune-mediated respiratory disease which manifests in childhood and results in substantial health burden. Each of these endpoints demonstrates substantial inter-individual variability enabling powerful systems biology tools to extract meaningful correlations. We will harmonize and study an IDEAL Meta-Cohort (IMC) comprised of longitudinal childhood cohorts enrolled in North America, Africa and Australasia. Our Clinical Core in Rochester, NY, is nationally prominent in the study of childhood immune ontogeny. Project (PR) 1 will employ cutting edge, cross- platform integrative bioinformatics tools to identify endotypes associated with clinical endpoints. PR2, will apply epigenetic analysis tools to the same samples and translate to host immune parameters the in silico-derived signatures. In PR3, key endotype-associated biomarkers and pathways will be dissected in vitro to establish cause and effect and identify agents (e.g., proteins, metabolites, adjuvants, vaccines) that may redirect IDEAL away from unfavorable endotypes and towards favorable ones. We have optimized sample-sparing assays to enable systems biology in infants and our published preliminary data demonstrate feasibility, robust IDEAL, and suggest distinct signatures by clinical status. Our cross- platform validation and correlation with endotypes correlating with clinical phenotypes will identify predictive/actionable biomarkers by i) characterizing IDEAL and microbiome in systemic/mucosal compartments (Overall Aim 1), ii) identifying endotype-specific biomarkers (Overall Aim 2), identifying in vitro interventions that re-direct IDEAL endotypes towards health (Overall Aim 3). Overall, we will enhance and accelerate discovery of new approaches to predict and prevent childhood disease.

项目摘要 迄今为止，定义和应用精确内分型的努力仅限于成人研究。然而，在这方面， 生命早期的免疫发育（IDEAL）是动态的，个体之间的差异表明， 对应于不同病理生理机制的内型将是年龄依赖性的。我们提出 因此，我们将研究定义明确的纵向儿童队列并在计算机上使用 对现有和前瞻性收集的数据以及年龄特异性人体体外模型进行综合分析 识别将IDEAL从疾病内型重定向到与疾病相关的内型的试剂的系统 健康我们选择了三个临床终点与系统生物学数据相关联，以确定IDEAL 内型：a）疫苗反应性，因为疫苗是最重要的生物医学干预， 减少儿童疾病; B）呼吸道感染，这是儿童最大的负担 感染性疾病;和c）哮喘，一种免疫介导的呼吸道疾病， 儿童期，造成巨大的健康负担。这些终点中的每一个都证明了 个体间的变异性使强大的系统生物学工具能够提取有意义的相关性。我们 将协调和研究由纵向儿童队列组成的IDEAL元队列（IMC） 在北美，非洲和澳大拉西亚注册。我们在纽约州罗切斯特的临床中心是全国性的 在儿童免疫个体发育的研究中非常突出。项目（PR）1将采用尖端，交叉- 平台整合生物信息学工具，以确定与临床终点相关的内型。PR 2，将 将表观遗传学分析工具应用于相同的样本，并将其转化为宿主免疫参数， 硅衍生签名。在PR 3中，关键的内型相关生物标志物和途径将在 体外以建立因果关系并鉴定试剂（例如，蛋白质、代谢物、佐剂、疫苗）， 可以将IDEAL从不利的内型重定向到有利的内型。我们优化了 使婴儿系统生物学和我们发表的初步数据的样本保留测定 证明可行性，稳健的IDEAL，并根据临床状态提出不同的签名。我们的十字架- 平台验证和与临床表型相关的内型的相关性将确定 i）表征系统/粘膜中的IDEAL和微生物组， ii）鉴定内型特异性生物标志物（总体目标2）， 将IDEAL内型重新导向健康的体外干预（总体目标3）。总的来说，我们将加强 并加速发现预测和预防儿童疾病的新方法。